Liver Toxicity is not Increased with Nevirapine Once a Day
Pablo Barreiro
Department of Infectious Diseases, Hospital Carlos III-La Paz University Hospital. Madrid, Spain
*Correspondence: Pablo Barreiro, Email not available
Abstract
In the 2NN study (van Leth, et al. Lancet 2004;363:1253-63), an international, multicenter, randomized,prospective trial in which nevirapine (NVP) oncedaily (QD) was compared to NVP twice daily andefavirenz (EFV), a higher incidence of liver enzymeelevations was found in the NVP QD arm with respectto the other two arms. In Dublin, during the 10th EuropeanAIDS Conference (EACS 2005), a sub-analysiswas presented (Storfer, et al. abstract PE9.6/2)in which it was highlighted that all the cases of excessliver toxicity due to NVP QD in the 2NN trialoccurred in a single center from Thailand.
